TMTPOST — Yuwell Medical said in its latest investor relations record that it is actively advancing U.S. Food and Drug Administration registration for its non-invasive ventilator products. The company’s respiratory therapy segment recorded year-on-year growth in the third quarter. Cooperation with Inogen is progressing, with plans to use Inogen’s channels to expand respiratory products in the U.S. market and strengthen supply-chain collaboration for cost reduction and resilience. Yuwell’s U.S. business remains at an early stage but is growing relatively quickly. The company plans to continue product registrations in relevant markets and expand localized channels and operations.